UKMi Information |
Information | MI News | ||
|---|---|---|---|---|
|
Welcome to the UK Medicines Information website. This site is designed to support the UKMi network. It hosts our strategy, policies, clinical governance standards and training materials, together with minutes of meetings of the UKMi Executive and its working groups. UKMi resources to support medicines management initiatives are hosted by the National electronic Library for Medicines (NeLM). Resources for the public can be found at NHS Direct. For UK health professionals, click on the map to search for your local medicines information centre. |
Medicines evaluation (LCNDG):Pertuzumab with docetaxel and trastuzumab for first-line HER2 positive metastatic or locally recurrent unresectable breast cancer, previously untreated or who have relapsed post adjuvant [LINK] NEW (15/05/2013)
Medicines evaluation (LCNDG): Brentuximab vedotin for systemic anaplastic large cell lymphoma [LINK] NEW (15/05/2013)
Medicines evaluation (LCNDG): Bendamustine with rituximab for relapsed indolent B-cell and mantle cell lymphoma including relapsed/refractoryWaldenstrÖm’s macroglobulinaemia [LINK] NEW (15/05/2013)
Medicines evaluation (LCNDG): Vismodegib for locally advanced or metastatic basal cell carcinoma [LINK] (09/05/2013)
Medicines Q&A: Document providing links to UKMi-produced Q&As on Evidence Search, organised by BNF category [LINK] (02/05/2013)
more >>> |





Medicines evaluation (LCNDG):Pertuzumab with docetaxel and trastuzumab for first-line HER2 positive metastatic or locally recurrent unresectable breast cancer, previously untreated or who have relapsed post adjuvant [





GHP/UKCPA 8th Joint National Conference Belfast